Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma

Journal of Endocrinological Investigation

Volumn 22, Issue 5, 1999, Pages 354-359

  Cannavò, Salvatore ^a,b   Curto L ^a   Squadrito, S ^a   Almoto, B ^a   Vieni, A ^a   Trimarchi, F ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Cabergoline; Dopamine agonists; Pituitary neoplasm; Prolactin

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOTENSION; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PREGNANCY; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0033000452     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343573     Document Type: Article

References (26)

1. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 1992, 13: 220.
2. Crosignani P.G., Ferrari C., Liuzzi A., Benco R., Mattei A., Rampini P., Dellabonzana D., Scarduelli C., Spelta B. Treatment of hyperprolactinemic states with different drugs: a study with bromocriptine, metergoline and lisuride. Fertil. Steril. 1982, 37: 61.
3. Franks S., Horrocks P.M., Lynch S.S., Butt W.R., London D.R. Effectiveness of pergolide mesylate in long-term treatment of hyperprolactinaemia. Br. Med. J. 1983, 286: 1177.
4. Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 1986, 63: 941.
5. Dallabonzana D., Liuzzi A., Opizzi G., Cozzi R., Verde G., Chiodini P.G., Rainer E., Dorow R., Horowski R. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J. Clin. Endocrinol. Metab. 1986, 63: 1002.
6. Rasmussen C., Bergh T., Wide L., Brownell J. CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion. Clin. Endocrinol. (Oxf.) 1987, 26: 321.
7. Benker G., Gieshoff B., Freundlieb O., Windeck R., Schute H.M., Lancranjan I., Reinwein D. Parenteral bromocriptine in the treatment of hormonally active pituitary tumours. Clin. Endocrinol. (Oxf.) 1986, 24: 505.
8. Kletzky O.A., Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia. Fertil. Steril. 1989, 51: 269.
9. Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 1989, 68: 1201.
10. Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hypeprolactinemic patients. J. Clin. Endocrinol. Metab. 1989, 69: 725.
11. Ferrari C., Paracchi A., Mattei A., de Vincentiis S., D'Alberton A., Crosignani P.G. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 1992, 126: 489.
12. Pellegrini I., Rasolonjanahary R., Gunz G., Bertrand P., Delivet S., Jedynak C.P., Kordon C., Peillon F., Jaquet P., Enjalbert A. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 1989, 69: 500.
13. Colao A., Di Sarno A., Samacchiaro F., Ferone D., Di Renzo G., Merola B., Annunziato L., Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 1997, 82: 876.
14. Delgrange E., Maiter D., Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur. J. Endocrinol. 1996, 134: 456.
15. Biller B.M.K., Molitch M.E., Vance M.L., Cannistraro K.B., Davis K.R., Simons J.A., Schoenfelder J.R., Klibanski A. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 1996, 81: 2338.
16. Ferrari C.I., Abs R., Bevan J.S., Brabant G., Ciccarelli E., Motta T., Mucci M., Muratori M., Musatti L., Verbessern G., Scanlon M.F. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin. Endocrinol. (Oxf), 1997, 46: 409.
17. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 1994, 331: 904.
18. Webster J., Piscitelli G., Polli A., D'Alberon A., Falsetti L., Ferrari C., Fioretti P., Giordano G., L'Hermite M., Ciccarelli E., Crosignani P.G, De Cecco L., Fadini R., Faglia G., Flamigni C., Tamburrano G., Ismail I., Scanlon M.F. (European Multicentre Cabergoline Study Group). The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin. Endocrinol. (Oxf), 1993, 39: 323.
19. Mattei A.M., Ferrari C., Baroldi P., Cavioni V., Paracchi A., Galparoli C., Romano C., Spellecchia D., Gerevini G., Crosignani P.G. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hypeprolactinemic patients. J. Clin. Endocrinol. Metab. 1988, 66: 193.
20. Molitch M.E. Pregnancy and the hyperprolactinemic woman. N. Engl. J. Med. 1985, 372: 1364.
21. Robert E., Musatti L., Piscitelli G., Ferrari C.I. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 1996, 10: 333.
22. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S., Cammarota T., Camanni M., Camanni F. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 1997, 20: 547.
23. Colao A., Di Sarno A., Landi M.L Cirillo S., Sarnachiaro F., Faccioli G., Pivonello R., Cataldi M., Merola B., Annunziato L., Lombardi G. Long-term and low-dose treatment with cabergoline induces macroprolactinomas shrinkage. J. Clin. Endocrinol. Metab. 1997, 82: 3574.
24. Chiodini P., Liuzzi A., Cozzi R., Verde G., Opizzi G., Dallabonzana D., Spelta B., Silvestrini F., Borghi G., Lucarelli G., Rainer E., Horowski R. Size reduction of macroprolactinomas by bromocriptine or lisuride treatment. J. Clin. Endocrinol. Metab. 1981, 53: 737.
25. Melis G.B., Gambacciani M., Paoletti A.M., Mais V., Sghedoni D., Fioretti P. Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil. Steril. 1989, 52: 412.
26. Muratori M., Arosio M., Gambino G., Romano C., Biella O., Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 1997, 20: 537.